Conclusions on the granting of the conditional marketing authorisation presented by the European 
Medicines Agency 
ANNEX IV 
52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions presented by the European Medicines Agency on: 
â€¢  Conditional marketing authorisation 
The CHMP having considered the application is of the opinion that the risk-benefit balance is favourable 
to recommend the granting of the conditional marketing authorisation as further explained in the European 
Public Assessment Report. 
53 
 
 
 
